[Report of the 6th German Interdisciplinary Congress of Intensive and Emergency Medicine. Initial experiences with the new anti-infective drug drotrecogin alfa (activated) in septic shock].
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007710:Klebsiella Infections / Q000188:drug therapy*; D007711:Klebsiella pneumoniae; D008297:Male; D008480:Mediastinitis / Q000188:drug therapy*; D008875:Middle Aged; D009102:Multiple Organ Failure / Q000188:drug therapy; D009204:Myocardial Revascularization; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D011486:Protein C / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012772:Shock, Septic / Q000188:drug therapy*; D013530:Surgical Wound Infection / Q000188:drug therapy*; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated
Bericht vom 6. Deutschen Interdisziplinären Kongress für Intensiv- und Notfallmedizin. Erste klinische Erfahrungen mit neuem Sepsis-Medikament drotrecogin alfa (aktiviert).